Key Drivers
- Strong cash
- Operating loss
- Very low leverage
AIAI Summary
MAZE has shifted from a financing-constrained speculative biotech to a better-funded, visibility-driven growth story—near-term dilution risk is materially reduced, making the MZE829 Phase II readout (or a meaningful partnership) the pivotal catalyst for upside while binary clinical outcomes and potential trial-driven burn/dilution remain the key risks to monitor.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash
- •Operating loss
- •Very low leverage
MAZE is cash-rich with very low leverage but has flipped from FY2024 profitability to a Q3 operating/net loss and negative free cash flow with zero reported revenue, indicating near-term cash burn despite ample liquidity.
Price Behavior
Key Price Behavior Insights:
- •Mild upward bias
- •Clustered resistance
- •Elevated volatility
Price is modestly above its last-month SMA (~$47.4), indicating a mild near-term up bias but with key support at $44.8–$45.6 and resistance at $51.0–$51.8 — a break below support or failure to clear resistance amid elevated short-term volatility would negate the bullish case.
Sharp multi-dollar swings (e.g., +$6 into 2026-03-10) signaling elevated short-term volatility
Sentiment & News
Key News Insights:
- •Investor presentation
- •No program updates
- •IR-focused timing
Maze Therapeutics will present at the TD Cowen healthcare conference on Feb 25, signaling investor outreach and corporate visibility rather than any new clinical, regulatory, or financing developments.
Limited near-term market impact—boosts visibility and analyst engagement but does not alter MAZE's clinical or financial fundamentals
Similar Companies in Healthcare
Other companies in the same sector with AI ratings